References:
1. National Institute of Neurological Disorders and Stroke. Huntington’s Disease: Hope Through Research. National Institutes of Health; 2020. NIH publication 20-NS-19. Accessed January 24, 2024. https://calalog-ninds.nih.gov/sites/detault/fles/publications/huntington%E2%80%99s-disease-hope-through-research_0.pdt
2. Antidopaminergic agents. Huntington’s Disease News. Accessed January 24, 2024. https://huntingtonsdiseasenews.com/antidopaminergic-agents/
3. Simpson JA, Lovecky D, Kogan J, Vetter LA, Yohrling GJ. Survey of the Huntington’s disease patient and caregiver community reveals most impactful symptoms and treatment needs. J Huntingtons Dis. 2016;5(4):395-403.
4. AUSTEDO® XR (deutetrabenazine) extended-release tablets/AUSTEDO® tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.
5. Tarapata K, Murray CF. A Caregiver's Guide to Huntington's Disease. Huntington's Disease Society of America; 2011. Accessed January 24, 2024. https://hdsa.org/wp-content/uploads/2015/03/A-Caregivers-Guide-to-HD.pdf
6. Burgess JC, Davis B, Fogarty E, et al. Caregiver Guide for Mid to Late Stage Huntington's Disease: For Long-Term Care Facilities and In-Home Care Agencies. Huntington's Disease Society of America; 2014. Accessed January 24, 2024. http://hdsa.org/wp-content/uploads/2015/04/CaregiverGuide_Mid_Late_StageHD.pdf
7. Caron NS, Wright GEB, Hayden MR. Huntington disease. In: Acam MP, Feldman J. Mirzaa GM. et al, eds. GeneReviews. University of Washington, Seattle, 1993-2024. Updated June 11, 2020. Accessed January 25, 2024. https://www.ncbi.nlm.nih.gov/books/NBK130S/